ClinicalTrials.gg
Status unknownNCT02142257Updated Apr 30, 2018

Comparison of Gastric Bypass and AspireAssist Aspiration Therapy for Treatment of Morbid Obesity

An observational study in Obesity, sponsored by Blekinge County Council Hospital. Status unknown at 1 site in Sweden. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by Blekinge County Council Hospital · Observational

How we know

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 179 studies in Obesity with a site in Sweden — 38 open to participants now, 49 under way, 8 of them phase 3. Obesity · Sweden.

Enrollment
16th of 30
100 · median 103
Started
2014
with 12 others
Observational
30 of 179
9 open now
Registered
79th of 179
by date

Among the 179 studies in Obesity with a site in Sweden, this one is the 16th largest by enrollment of the 30 observational ones that give a count, is one of 13 that started in 2014, is one of 30 observational ones, and was the 79th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

38 of the 179 studies in Obesity with a site in Sweden are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Obesity with a site in Sweden, or all of them as a file.
02

Study summary

The purpose of this study is to compare Gastric Bypass and AspireAssist Aspiration Therapy over 5 years of treatment with regards to weight loss, quality of life, complications, adverse events, and health economics.

Read the detailed description

Overweight and obesity is increasing rapidly in Sweden and is the greatest threat to future public health. Obesity, defined according to the World Health Organization (WHO) as a body mass index (BMI) greater than 30 kg/m2, is an intractable disease in healthcare today. Obesity results in reduced life expectancy and increased morbidity.

Weight reduction by lifestyle changes or with different pharmacological preparations have in many studies not made lasting long term results. Obesity surgery has so far been the only way to achieve permanent weight loss. During the 1980s, restrictive procedures were performed, e.g., vertical banded gastro-plasty (VBG) with good but unfortunately transient effect. Later developed, is the now prevalent gastric bypass procedure (GBP) which today uses the keyhole technique and causes combined restrictive and mal-absorptive changes in gastrointestinal anatomy.

GBP is currently the standard method in clinical practice for the surgical treatment of morbid obesity (i.e., BMI over 35). GBP is a procedure that is not reversible, which entail certain pre - and postoperative risks. GBP quickly brings a sharp reduction in weight and also regression of diabetes mellitus type 2. Unfortunately, the surgery cause lifelong mal-absorption and requirements of vitamin and mineral supplements.

Swedish Obese Subjects study (SOS) that emanated from Gothenburg was the first controlled intervention study of overweight individuals. Approximately 4000 patients were included, half of which were surgical, the other half were treated optimally, but without surgery. The patients have been followed for 10-20 years. Total mortality was 24% lower in the surgical group.

A new alternative approach to obesity surgery, AspireAssist™ Aspiration Therapy System (CE Marked), comes from the United States and in this method the individual empties out digesta from the stomach. Percutaneous endoscopic gastrostomy (PEG) has been used internationally since the early 1980s for nutrition therapy for stroke or cancer. In a gastroscopy a tube is placed between the stomach and abdominal wall and nutrition administered via tube directly into the stomach.

Aspiration treatment with AspireAssist™ empties food from the stomach after every meal to lose weight. Using a valve mechanism and associated tubing set and water reservoir the individual empties out digesta in the toilet 20 minutes after each meal and loses approximately 30% of the caloric intake in the diet. A 1 -year study in Karlskrona, Sweden, has shown a significant reduction in weight, almost 40% Excess Weight Loss (% EWL) reduction and median weight reduction of 16.5 kg after 6 months. For GBP the weight reduction of 1 year is in the order of 70-85 %. During 1 year of treatment with AspireAssist™ there were no serious complications or problems with the body's electrolyte balance noted either at the surgery or during follow-up. The advantage of this method is that it is completely reversible and the individual who does not wish to continue aspiration may have the tube into the stomach removed. GBP results in most of the stomach becoming disconnected and not accessible for the diagnosis of, for example, ulcers, bleeding, tumors or gall stones. AspireAssist™ does not have any lasting changes in the anatomy and thus will not lead to the potential for internal hernia that GBP unfortunately can cause. Wound infection occurs in approximately 9 % of cases when PEG tubes are placed in patients with cancer or stroke. Wound infections are, in most cases, treatable with antibiotics in tablet form and are very rarely considered to be a serious complication. Antibiotics are routinely given in conjunction with PEG insertion. Very unusual complication is leakage associated with insertion of the PEG and the method has been reported to have a risk of about 2 % during PEG insertion.

For the individual to get help to change their habits and their lifestyle, cognitive behavioral therapy (CBT) is included in the treatment concept for AspireAssist™. CBT program runs for six months and includes both group meetings and individual conversations and individual assignments between meetings. Group meetings will cover the following themes: motivation, vision workshop, self-esteem, thought management, stress, learn to eat consciously, prevent and manage relapse. The program uses no calorie reducing methods since there is no scientific evidence that these provide permanent results but are based on CBT. The program is enhanced with awareness and mental training, which are methods that have shown good results in stress-related conditions. Mindfulness Based Stress Reduction (MBSR) in one study has been shown to change brain activity of the participants so that the activity was shifted from the areas in the frontal lobe that is active during stress, anxiety and depression to areas that regulate peace, joy and curiosity.

Randomization in clinical trial (RCT) had been the best way to implement such a comparative study. But AspireAssist™ method is aimed at patients who do not want or dare to be operated with Gastric Bypass Procedure (GBP) and therefore fails to randomization.

We therefore recruit patients from the clinic's waiting list of accepted and planned the GBP and the other group comes from the existing waiting list for Aspire method to treat obesity. This group includes only those patients who expressed clearly that they are not willing or dare to be operated with GBP, but instead wishes to receive treatment with Aspire method for their morbid obesity.

There are now newer statistical methods to compare two or more groups in an observational study in a good and statistically significant manner and Stata version 13 can handle it well by matching the so-called covariates (e.g., in our study may be covariates following variables at baseline: age, gender, preoperative weight, BMI, concomitant disease such as diabetes). Patients were matched and then the comparison is done between the matched groups. Calculation of treatment effects , including so-called propensity score exploitation has already been used in a comparative study between GBP and other bariatric surgery for obesity where neither has been able to randomize patients (Carlin et al Annals of Surgery, Vol. 257, Number 5, May 2013: 791-7)

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Gastric Bypass
  • Aspiration Therapy
  • AspireAssist
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study is a prospective investigation of patients in Blekinge with a diagnosis of obesity. A total of 100 patients will be included consecutively in the study. The distribution will be 50 patients for each group. Recruitment for Gastric Bypass is made from the clinic's waiting list for obesity surgery and for AspireAssist those individuals' self-reported interest for treatment with AspireAssist.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 20-60 years
  • over 35
  • the absence of an eating disorder
  • severe co-morbidity
  • failure to achieve weight loss with lifestyle changes or other conservative approaches

Exclusion criteria

Exclusion Criteria:

  • Recent myocardial infarction (3 months)
  • Ongoing cancer
  • Chronic liver and / or kidney disease
  • Mental illness, including substance abuse and eating disorders that can exclude the patient from aspiration therapy.
  • Discovery of severe disease of the stomach on endoscopy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Gastric Bypass

    Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.

    Procedure: Gastric Bypass

  • AspireAssist Aspiration Therapy

    Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.

    Device: AspireAssist Aspiration Therapy

Interventions

  • ProcedureGastric Bypass

    Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.

  • DeviceAspireAssist Aspiration Therapy

    AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.

06

What researchers measure

Primary outcomes

  1. Weight Loss

    % Excess Weight loss based on ideal body weight with BMI of 25

    Time frame: year 1 - quarterly, years 2-5 once per year

Secondary outcomes

  1. Quality of Life

    Quality of Life survey according to EQ-5D EuroQol survey

    Time frame: annually, up to 5 years

Other outcomes

  1. Complications

    any surgical or post surgical complications, therapy related illness or adverse events

    Time frame: within 30 days of procedure, after 30 days

07

Study locations

1 site
  • Blekinge County Council Hospital
    Karlskrona, 371 85, Sweden
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2014 (actual). Primary completion is estimated for May 2020, 72 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 72 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2014
First posted
May 20, 2014
StartActual
May 2014
Primary completionEst.
May 2020
CompletionEst.
May 2020
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02142257
Lead sponsor
Blekinge County Council Hospital
Responsible party
Max O Nystrom (Dr Max O Nystrom, Blekinge County Council Hospital) — Principal investigator
First posted
May 20, 2014
Start date
May 2014
Primary completion
May 2020 (estimated)
Completion
May 2020 (estimated)
Last update
Apr 30, 2018

Study contacts

Max O Nystrom, MD
principal investigator · Blekinge County Council Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion